Acta Medica Okayama volume74 issue1
2020-02 発行

A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

Kada, Akiko Clinical Research Center, NHO Nagoya Medical Center
Fukano, Reiji Department of Pediatrics, Yamaguchi University Graduate School of Medicine
Mori, Tetsuya Department of Pediatrics, St. Marianna University School of Medicine Hospital
Kamei, Michi Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences
Tanaka, Fumiko Department of Pediatrics, Saiseikai Yokohamashi Nanbu Hospital
Ueyama, Junichi Department of Pediatrics, Tottori University Hospital,
Sekimizu, Masahiro Department of Pediatrics, NHO Nagoya Medical Center
Osumi, Tomoo Children’s Cancer Center, National Center for Child Health and Development
Mori, Takeshi Department of Hematology and Oncology, Children’s Cancer Center, Kobe Children’s Hospital
Koga, Yuhki Department of Pediatrics, Graduate School of Medical Sciences Kyushu University
Ohki, Kentaro Department of Pediatric Hematology and Oncology Research, National Center for Child Health and Development
Fujita, Naoto Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital
Mitsui, Tetsuo Department of Pediatrics, Yamagata University Hospital
Saito, Akiko M. Clinical Research Center, NHO Nagoya Medical Center
Hashimoto, Hiroya Clinical Research Center, NHO Nagoya Medical Center
Kobayashi, Ryoji Department of Pediatrics and Adolescence, Sapporo Hokuyu Hospital
Publication Date
2020-02
Abstract
No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/m2/day) for five days plus melphalan (70 mg/m2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.
Document Type
Clinical Study Protocol
Keywords
anaplastic large-cell lymphoma
relapsed/refractory
fludarabine
melphalan
total body irradiation
Link to PubMed
Thumnail 74_1_89.pdf 1.89 MB